introduction Humanpapilloma virus (HPV) infection of the oropharynx has recently been recognized to play a role in the pathogenesis of head and neck squamous cell carcinomas along with the use of tobacco and alcohol [1] [2] [3] [4] [5] [6] [7] [8] .
A recent meta-analysis showed that patients with HPVpositive oropharyngeal cancer (OPC) have a better prognosis than those with HPV-negative tumors [9] . The molecular mechanisms underlying HPV tumorigenesis are mainly mediated through its two major oncoproteins E6 and E7, inactivating p53 and pRb, respectively [10] . In particular, E7 binds to and degrades Rb, releasing E2F, leading to p16 overexpression, which is associated with superior clinical outcome. Therefore, p16 has been suggested as a surrogate marker for HPV positivity in OPC [11] [12] [13] 14] .
The longest established nonsurgical treatment of advanced OPC (stage III and IV) consists of standard fractionated radiotherapy (RT) with chemotherapy (CT), particularly cisplatin [15, 16] . A recently reported large phase III trial of the Radiation Therapy Oncology Group (RTOG 0129) revealed no differences in the overall survival (OS) and progression-free survival rates between accelerated fractionation and standard fractionation when combined with concurrent high-dose cisplatin [1] . The success rate in collecting a high number of pretreatment tumor specimens enabled the investigators to establish firmly that the tumor HPV status is to date the strongest independent prognostic factor in patients treated with radiation-cisplatin regimen [1] . In addition, the investigators were able to divide patients into categories of low, intermediate or high risk of death based on HPV status, smoking history and tumor stage [1] . In patients with HPV-positive tumors, the number of pack-years of tobacco smoking (≤10 versus >10) and nodal stage (N0 to N2a versus N2b to N3) were additional determinants of OS rates. Conversely, in those with HPV-negative carcinomas, OS rates segregated according to tobacco smoking and tumor stage (T2 or T3 versus T4) [1] .
Because of its important clinical implication and application, it is prudent to test whether the RTOG recursive partitioning analysis (RPA) model also holds for patients treated with regimens other than radiation plus concurrent cisplatin. Therefore, we undertook this study in a single-institutional retrospective series of patients with OPC, which validated the model in an independent cohort.
patients and methods
We collected data on 140 consecutive patients with OPC treated at our institution from 2003 to 2009. Complete information regarding HPV status, pack-years of tobacco smoking and tumor stage were available for 120 patients, who were included in the present study.
treatment modalities
Patients were treated with induction CT followed by chemoradiation (n = 39), chemoradiation (n = 64) or RT only (n = 17 Radiotherapy was delivered using either three-dimensional radiotherapy (3DRT) (n = 70) or intensity-modulated radiation therapy (IMRT) (n = 50) techniques. With 3DRT approach, either conventional fractionation (CF: 66-70 Gy/33-35 fractions/6.5-7 weeks) or accelerated fractionation with concomitant boost (AF-CB: 72 Gy/40 fractions/6 weeks with twice-a-day treatment during the last 10 days) were used. The IMRT regimens consisted of sequential IMRT based on conventional fractionation (70 Gy/ 35 fractions) or accelerated IMRT with 66 Gy/30 fractions/6 weeks or 70 Gy/33 fractions/6.5 weeks.
immunohistochemical analysis
All patients were stratified according to tumor p16 expression as assayed by immunohistochemical analysis of 2-μm sections formalinfixed and paraffin-embedded specimens and using the CINtec Histologic Kit (MTM Laboratories AG, Heidelberg, Germany), following manufacturer's instructions. The antigen was retrieved in an autoclave at 95°C for 15 min; the primary antibody was incubated for 1 h at room temperature. The reaction was developed using 3,3 0 -diaminobenzidine as chromogen for 10 min at room temperature. Positivity was defined as >50% of cells showing/strong nuclear and cytoplasmic immunolabeling. comparison between the curves was carried out using the log-rank test. OS time was computed from the date of starting therapy to the date of death due to any cause, censoring at the date of last available follow-up assessment for living patients. As a measure of the between-curves separation, we used the Harrell C-index [17] ; the latter may vary between 0.5 and 1.0, respectively, indicating lack of or perfect discrimination. Moreover, a descriptive analysis was carried out by comparing the 2-year OS rates of the present three groups versus those of the RTOG series (the latter were kindly provided by a coauthor); such a comparison was carried out graphically by means of a scatterplot and by fitting a linear regression line.
We additionally estimated the crude cumulative incidence curves of disease relapse, in the whole series and stratified by risk groups. Such an analysis was carried out in a competing risk framework; the event competing with relapse was death without evidence of OPC. Time was censored at the date of last available follow-up assessment in patients who were alive and relapse free. The Gray test was used to perform betweengroups comparisons of cumulative incidence curves [18] .
P values <0.05 were considered significant. The SAS statistical package [19] and R software [20] were used for the analyses.
results Figure 1 shows the distribution of our population according to the RTOG RPA analysis. Most of our patients were categorized as high risk (group 3; n = 48), followed by intermediate (group 2; n = 46) and low risk (group 1; n = 26).
The baseline patients and tumor characteristics are listed in Table 2 . The median age for the whole group was 61 years (range: 37-88). The majority of patients were males (80%) and had T4 tumor (41.7%) or stage IVa disease (75.8%) by the AJCC staging system. The median number of cigarette packyear consumption was 30 (range: 0-120). Finally, more than half of the patients showed a p16-positive OPC (54.6%). Most patients (53.3%) were treated with chemoradiation, followed by induction CT plus chemoradiation (32.5%) and RT only (14.2%). With a median follow-up of 23 months (interquartile range: 13-39 months), 21 patients have died, 11 of whom after disease recurrence, and 1 patient with relapse was alive at last follow-up.
Stratification of patients according to the RTOG risk stratification scheme yielded statistically significant differences between the three groups for N stage (P = 0.006), number of cigarette packs per year (P = 0.001) and p16 expression (P = 0.001). Also, statistically significant difference was observed for type of treatment (P = 0.037); nevertheless, in the whole series, type of treatment was not significantly associated with patient's survival as shown in Figure 2 (P = 0.164).
After stratification of patients according to the different treatment (induction CT + CT-RT, CT-RT or RT), the RTOG risk scheme confirmed its ability in discriminating patient survival, though the power to detect statistical significance was 
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limited by the small sample size in each subgroup (data not shown). Figure 3 shows the OS curves in the whole series (left panel) and in the three risk groups (right panel). No deaths were observed in group 1 (26 patients), whereas 7 patients died in group 2 (46 patients) and 14 in group 3 (48 patients). The 3-year OS estimates (95% confidence interval) for the whole series was 80% (71.6%-89.3%), 100% in group 1, 79.6% (65.2%-97.3%) in group 2 and 70% (56.6%-86.5%) in group 3. The difference between the three curves was statistically significant according to the log-rank test (P = 0.009). Figure 4 shows a concordance plot of the 2-year OS estimates in our series versus those of the RTOG study. The 2-year estimates were chosen for comparison because the short follow-up in this series affected the precision of survival estimates at later times. Overall, the concordance between our rates and the original ones was fairly good, with a 6.5%, 5.9% and 16.3% survival advantage in group 1, 2 and 3, respectively. Consequently, the least-squares regression line (dotted) was above and shallower relative to the perfect concordance line (continuous), indicating that OS in this single institutional series was generally higher and less divergent than in the RTOG series. Finally, the Harrell's C-index adjusted for optimism was 0.70, indicating a fairly good discriminating ability of the RPA model classification.
discussion
The survival of patients with advanced OPC may differ significantly between individuals. Consequently, the ability to estimate survival probability of OPC patients before any type of treatment would be very valuable for decision making, as well as for developing clinical trials. At present, only few studies addressed this topic and proposed models for stratifying patient survival based on combinations of several pretreatment characteristics [11, 12, 21] .
In a recent study based on a phase III trial population, Ang et al. [1] proposed a new risk stratification scheme, which divided the survival of patients with OPC into three groups according to HPV status, smoking history and tumor stage. The objective of the current study was to validate the risk grouping proposed by RTOG investigators using a singleinstitutional database and using p16 expression as surrogate of HPV status. Indeed, the use of p16 has been validated in several studies including the present one [11] [12] [13] 14] .
Our analyses confirmed the results of the RTOG series. Specifically, patients in the low-risk category ( p16 positive, ≤10 pack-years or >10 pack-years but < N2b) had a 100% OS rate at 2 years. In contrast, patients in the intermediate-risk group ( p16 positive, ≥N2b and >10 pack-years or p16 negative, <T4 and ≤10 pack-years) had an 84.9% OS rate at 2 years and those in the high-risk category ( p16 negative, >10 pack-years and T4 tumors) had a 70.3% OS rate at 2 years. Our study showed similar 2-year outcomes to those reported by Gillison et al., where HPV-positive OPC showed a better OS relative to their HPV-negative counterparts [2-year OS: 87.5% (82.8-92.2) versus 67.2% (58.9-75.4); P < 0.0001] and demonstrated that patients with HPV-negative tumors who smoked ≥20 pack-years had a 4.3-fold higher risk of death relative to those with HPV-positive tumors and smoked <20 pack-years [22] .
It is noteworthy that, in our study, the majority of patients were in the high-risk group (n = 48), followed by patients in the intermediate-(n = 46) and low-risk (n = 26) categories. Conversely, in the RTOG series, the majority of patients presented with a low-risk disease. This difference may be related to different life habits between European and USA patients. For example, in our population, the median number of cigarette pack-years was particularly high (n = 34). Therefore, while most of our patients had HPV-positive tumors, the higher number of cigarette pack-years resulted in a higher number of patients classified as having an intermediaterisk disease.
There are also differences in the incidence and presentation of OPC between European and USA patients as shown in a recent European study revealing an increase in the incidence of OPC in individuals >50 years of age [23] . In contrast, the incidence of HPV-related carcinoma increased only in patients between 40 and 59 years of age.
Despite the observed differences in the risk distribution, our study showed that the RTOG risk stratification scheme may be widely used as it represents a simple and accurate tool for determining different OS strata even in unselected European OPC population.
Interestingly, the biology of OPC is becoming more important in determining the prognosis than other features. In this context, a TNM (tumor-node-metastasis) revision for OPC has been proposed by Fisher et al. based on p16 positivity [24] . Similarly, a recent study showed that pretreatment EGFR expression significantly improved the ability to predict OS and local recurrence rates in OPC patients treated with RT [25] . More complex determinations showed that low EGFR and high p16 expression are markers of good response to organ-sparing therapy and outcome, whereas high EGFR expression, combined low p53/high Bcl-xL expression, female gender and original articles Annals of Oncology smoking are associated with a poor outcome [12] . Our results corroborate the clinical usefulness of such composite models though refinement by treatment modality and other variable need to be further pursued.
Our study has a couple of limitations. First, our patients received different treatments (induction CT + CT-RT or CT-RT or RT alone), which reflects the institutional treatment policy that, e.g. reserve radiation alone for patients presenting with early-stage tumors. This variability can confound risk classification and the number of patients included in the current study is quite small, reflecting a single-institutional study. However, outcome analysis following RPA criteria turned out to separate risk groups independently of the treatment received, thus potentially confirming the validity of the RTOG risk grouping in different treatment settings. Therefore, multi-institutional efforts should be undertaken to further strengthen the results in larger cohorts.
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